The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review
Chellappan, DK
Leng, KH
Jia, LJ
Aziz, NABA
Hoong, WC
Qian, YC
Ling, FY
Wei, GS
Ying, T
Chellian, J
Gupta, G
Dua, K
- Publication Type:
- Journal Article
- Citation:
- Biomedicine and Pharmacotherapy, 2018, 102 pp. 1127 - 1144
- Issue Date:
- 2018-06-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| 1-s2.0-S0753332218310060-main.pdf | Published Version | 2.32 MB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
© 2018 Elsevier Masson SAS Objective: The study aims to analyze the effectiveness of bevacizumab in addressing the complications associated with gynecological cancers and evaluates effective treatments for various gynecological cancers. Methods: The study follows a systematic review approach that has been implemented to analyze the qualitative published data from previous studies. Studies related with the trials of angiogenesis and bevacizumab were selected in the review. Results: In general, the management of gynecological cancers include chemotherapy, surgery and radiation therapy. Results suggest bevacizumab as an effective treatment modality for cervical and several other cancers. Overall, bevacizumab showed promising results in improving the overall survival rate of gynecological cancer patients through the combination of bevacizumab with other chemotherapeutic agents. Conclusion: Bevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents. The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent(s) that were used with bevacizumab in combination therapy. Overall, bevacizumab effectively improved the survival rate in patients with several gynaecological cancers.
Please use this identifier to cite or link to this item: